When treatment helps, but you’re still making plans around a possible flare, there’s more to discuss than the number of hives ...

Asian and giant hornets have established colonies in key northern Moroccan production zones, causing the destruction of ...

I developed hives at the beginning of July. The symptoms dragged on, and I was subsequently diagnosed with "chronic urticaria."At first, it was somewhat controlled by a mild antihistamine, but the ...

FDA approves 1st-of-its-kind chronic hives treatment, Novartis' Rhapsido, for adults with symptomatic dermographism unresponsive ...

Novartis gets US FDA nod for Rhapsido to treat symptomatic dermographism; expanding its use beyond chronic spontaneous urticaria: Basel Friday, October 9, 2026, 15:00 Hrs [IST] No ...

The recent FDA approval of remibrutinib (Rhapsido) for symptomatic dermographism (SD) gives clinicians an on-label option for a condition long managed with off-label therapies, Raj Chovatiya, MD, PhD, ...

FDA expands Novartis remibrutinib use for adults with symptomatic dermographism, a chronic skin condition causing recurring ...

The FDA has approved Rhapsido (remibrutinib) for adults with symptomatic dermographism who remain symptomatic despite use of ...

The approval will allow the drugmaker to expand the use of its Bruton tyrosine kinase inhibitor, already approved for chronic ...

LEO Pharma, Inc., a global leader in medical dermatology, today announced its scientific program for the 2026 Fall Clinical Dermatology Conference, taking place October 8-11 in Las Vegas, Nevada.

The FDA has approved an expanded indication for remibrutinib as the first treatment for adults with symptomatic dermographism ...